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Summary-lnteractions of p-opioid receptors with the benzodiazepine system were studied by examining 
the modulatory effects of flumazenil (a benzodiazepine antagonist) and alprazolam (a benzodiazepine 
agonist) on the respiratory effects ofthe opioid peptide dermorphin. Dermorphin, 1-30 nmol administered 
i.c.v., to conscious, unrestrained rats decreased ventilation rate (VR) and minute volume (MV) 
dose-dependently. The ventilatory depression was antagonized by naloxone and by the benzodiazepine 
antagonist flumazenil. The benzodiazepine alprazolam potentiateri the respiratory inhibition of a small 
(I nmol) dose of dermorphin but antagonized that of a higher dos:~ (3 nmol). The results suggest that the 
benzodiazepine/GABA receptor complex modulates respiratory depression induced by centrat p-receptor 
Stimulation in the rat. 
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Dermorphin is a heptapeptide (Tyr-o-Ala-Phe-Gly-
Tyr-Pro-Ser-NH2) originally extracted from the frog 
skin (Montecucchi, De Castiglione, Piani, Gozzini 
and Erspamer, 1981). As a potent and selective opioid 
J.t-receptor agonist (Rossi, De Castiglione and Perseo, 
1985; Krumins, 1987; Lazarus, Guglietta, Wilson, 
Irons and De Castiglione, 1989) it depresses respir-
ation (Feuerstein and Faden, 1983; Paakkari, Paak-
kari, Siren and Feuerstein, 1990). 
y-Aminobutyric acid (GABA) modulates various 
opioid effects, as shown in studies describing the 
interactions of GABA or benzodiazepine agonists 
and antagonists with opioid-induced analgesia 
(Zonta, Zambotti, Vincentini, Tammiso and 
Mantegazza, 1981; Mantegazza, Parenti, Tammiso, 
Vita, Zambotti and Zonta, 1982; Andree, Kendall 
and Enna, 1983; Brady, Mansbach, Skurdal, 
Muldoon and Barrett, 1984; Zambotti, Zonta, 
Tammiso, Conci, Hafner, Ferrario, Zecca and 
Mantegazza, 1987). The intestinal effects of morphine 
(Fioramonti, Fargeas and Bueno, 1987) and the 
cataleptic effect of dermorphin (Paakkari and 
Feuerstein, 1988) were reversed by the selective 
benzodiazepine receptor antagonist flumazenil 
(Hunkeler, Möhler, Pieri, Pole, Bonetti, Cumin, 
Schaffner and Haefely, 1981 ). On the other hand, 
various effects of benzodiazepines--e.g. effects on 
conflict or feeding and drinking behavior (Lorens and 
Sainati, 1978; Duka, Cumin, Haefely and Herz, 1981; 
•To whom correspondence should be addressed. 
Cooper, 1983) and on growth hormone secretion 
(Huupponen, Koulu, Pihlajamäki and Mäkinen, 
1986)--have been attenuated by the opiate antagonist 
naloxone. 
In the present study the selective benzodiazepine 
antagonist ftumazenil or the benzodiazepine alprazo-
lam were given prior to dermorphin to investigate 
whether opioid and benzodiazepine receptors also 
interact in mediating the respiratory effects of this 
Jl. ·opioid agonist peptide. The experiments were con-
ducted in conscious, freely moving rats to avoid the 
effects of anaesthesia and restraint on resp1ration. 
METHODS 
Conscious male Sprague-Dawley rats (25(}-330 g, 
Taconic Farms, Germantown, New York) were used. 
The animals received standard rat pellets and water 
ad libitum and were kept at 22°C and 12 hr Iight--dark 
cycle. 
Procedures for drug administration 
Rats were anesthetized with an intramuscular in-
jection of ketamine ( 130 mg/kg) and acepromazine 
(1.3 mg/kg). A stainless steel guide cannula was 
stereotaxically inserted (DKI, Califomia) through the 
skull into the right lateral brain ventricle (i.c.v.) and 
fixed with glue (Eastman 910 adhesive). Coordinates 
for the lateral ventricle were AP = -0.8 mm and 
L = 1.2 mm. After the operation the rats were al-
lowed to recover 2-3 days. On the day of the 
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experiment, a 7.5 mm long 30 g cannula was inserted 
into the ventricular space through the guide cannula. 
The injection cannula was connected via polyethylene 
tubing to a Hamilton microliter syringe and the drug 
solution was injected over a period of 20 sec in a 
volume of 10 .ul. The proper position of the i.c.v. 
cannula was ascertained at the end of the experiment 
by dissection of the brain after an injection of meth-
ylene blue (10 J.ll). 
Recording of respiration 
Ventilation rate (VR) and relative ventilation tidal 
volume (TV) were monitared by the Oxymax 85 
system (Columbus Instruments, Columbus, Ohio). 
The recording system consists of 2 sealed plexi-glass 
test chambers and one reference chamber (internal 
dimensions: 112 x 197 x 297 mm, volume: 6.55liter). 
Room air is pumped through each chamber at the 
constant rate of 21/min. Recording of the relative 
tidal volume and respiration rate is based on the 
minute pressure changes in the chamber caused by 
the subject's breathing. Tidal volume and calculated 
minute volume (MV) are expressed as arbitrary units. 
The animals were allowed a 60 min of adaptation 
to the Oxymax plexiglass chamber prior to drug or 
vehicle administration. The respiratory data were 
gathered at 2 min intervals and averages of 5 consecu-
tive recordings were calculated. The animals received 
the pretreatments (alprazolam, flumazenil or nalox-
one) 20 min prior to the i.c.v. administration of 
dermorphin. To minimize the interference of the 
animal handling on the respiratory results only the 
data prior to the pretreatment and those 30-50 min 
after the last drug injection were used. The base lines 
of the respiratory variables were calculated as aver-
ages of 5 consecutive measurements. i.e. 10 min 
period before the drug injection. 
Drugs 
Dermorphin (Sigma Chemical Company) and 
naloxone (kindly provided by DuPont Pharmaceuti-
cals, Wilmington, Delaware) were dissolved in 0.9% 
NaCI. Flumazenil (gift from W. Haefely. Hoffmann-
LaRache Inc., Basel, Switzerland) was dissolved in 
10% Emulphur 620 (GAF corp.)--ethanol mixture 
(1: 1), warmed and sonicated immediately before i.p. 
administration. Alprazolam (Upjohn Co., Kalama-
zoo, Michigan) was disso1ved in a solution of 10% 
ethanol, 40% propyleneglycol and 50% of 0.9% 
NaCl. Naloxone, flumazenil and alprazolam were 
administered i.p. in a volume of 0.3 ml 20 min before 
dermorphin injection when used as pretreatment. 
Statistics 
The data in text and figures are mean values ±SE 
for 6-8 rats in each group. Some results are expressed 
as areas under the curves and the x-axes for the 
period of 30-50 min after drug injections (area 
scores). For ca1culation of area scores the trapezoidal 
method i.e. geometric approximation by means of 
rectangles and triangles was used. The homogeneity 
of variances was tested with Bartlett's test. Groups 
with variances not significant1y unequal were tested 
with one-way analysis of variance (ANOV A) fo1-
lowed by the multiple comparison test of New-
man-Keul. Repeated observations within the same 
groups were analyzed with two-way ANOVA for 
repeated measures. For comparisons of repeated 
measurements within a group t-test for dependent 
means was used. For groups with significantly un-
equal variances the Kruska1-Wallis testwas used. In 
case of a significant Kruskal-Wallis P-value the 
Dunn procedure was used for comparisons between 
several means. 
For calculations the CSS: Statistica1 Software 
Package (StatSoft Inc., Tulsa, Ok1ahoma, release 3.0 
C) for personal computers was used. 
RESULTS 
Effects of dermorphin i.c.v. on ventilation 
Dermorphin 1, 3 and 30 nmol dose-dependently 
decreased ventilation rate (VR) to 74 ± 14% 
(P < 0.10), 54± 9% (P < 0.01) and 35 ± 6% 
[P < 0.01, dependent t-test, Figs 1(A), 2(A) and 3(A)] 
from the initiallevel, respectively. The corresponding 
effects on ventilation minute volume (MV) were 
103 ± 19% (P = 0.98), 46 ± 6% and 41 ± 7% from 
the initial Ievel, respectively [Figs l(C), 2(C) and 
3(C)]. The dermorphin-induced effects on ventilatory 
tidal volume (TV) were variable including increases at 
doses 1 or 30 nmol/kg (maxima: 131 ± 14% and 
130 ± 14%, both P < 0.05) and a negligible effect at 
3 nmol/kg (104 ± 16%, P = 0.40, Fig. 4). Figures 
1 (B), (D), 2(8), (D), 3(8) and (D) show the corre-
sponding area scores from samples 94-144 min post 
injection. 
Interaction of na/oxone and dermorphin 1 nmo/ 
Pretreatment with naloxone (5 mg/kg, i.p.) antago-
nized the dermorphin-induced decrease in VR 
(Fig. I). Likewise the concomitant increase in TV was 
attenuated by naloxone [Fig. 4(A)]. As could be 
expected, naloxone did not modify the negligible 
effect of dermorphin 1 nmol on MV (Fig. 1 ). 
Interaction of a/prazo/am and dermorphin 
Pretreatment with alprazolam (I mg/kg, i.p.) did 
not alter the bradypneic effect of dermorphin l nmol 
while the dermorphin-induced increase in TV was 
completely abolished (Figs 1 and 4). Consequently, 
the combination alprazolam plus dermorphin re-
sulted in a significant decrease in MV [Fig. 1 (C) and 
(D)]. At dermorphin 3 nmol the alprazolam pretreat-
ment (I mg/kg, i.p.) slightly attenuated the dermor-
phin induced decrease in VR [Fig. 2(A) and (B)]. As 
the result of this and the concomitant slight increase 
of TV in the pretreatment group, the net effect 
alprazolam plus d~rmorphin combination on MV 
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was attenuated as compared to dermorphin alone 
[Fig. 2(C) and (D)]. 
Interaction of flumazeni/ and dermorphin 
At dermorphin dose of 1 nmol the pretreatment 
with ftumazenil (5 mg/kg, i.p.) clearly reverted the 
decrease in VR by dermorphin alone (about -80% 
from baseline) to an increase of about 110% from 
baseline [Fig. 1 (A)]. Concomitantly the dermorphin-
induced increase in TV was reverted to a slight 
negative shift [Fig. 4(A)] resulting in MV to a net 
effect close to the baseline and not significantly 
different from dermorphin alone [Fig. I (C) and (D)]. 
Flumazenil antagonized the bradypneic effect of 
dermorphin 3 nmol [Fig. 2(A) and (B)] while neither 
dermorphin alone or fiumazenil plus dermorphin 
significantly changed TV [Fig. 4(8)]. As a net effect 
fiumazenil pretreatment antagonized the dermorphin 
induced decrease in MV. Dermorphin alone de-
creased MV by about 50% while after ftumazenil 
pretreatment the decrease was 30%. 
Flumazenil almost completely aboJished the strong 
bradypneic effect of dermorphin 30 nmol [Fig. 3(A) 
and (B)] while increase in TV by dermorphin was 
slightly increased (Fig. 4). As the result MV was not 
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significantly altered in reference to the base line in the 
presence of the pretreatment in cantrast to the streng 
decrease by dermorphin alone to about 40% of the 
initial Ievel. 
DISCUSSION 
The strong respiratory depressant effect of dermor-
phin was abolished by ftumazenil, a specific benzo-
diazepine antagonist which does not revert the effects 
of other central nervous depressants such as barbitu-
rates, meprobamate, ethanol or valproate (Bonetti, 
Pieri, Cumin, Schaffner, Pieri, Gamzu, Muller and 
Haefely, 1982; Barrett, Brady and Witkin, 1 985; 
Masur, Silva-Filho, de Souza and Pires, 1987). It has 
been reported previously that ftumazenil antagonized 
the antinociceptive (Brady et al., 1984) and intestinal 
(Fioramonti, Fargeas and Bueno, 1 987) effects of 
centrally administered morphine or DAMGO, and it 
prevented also the cataleptic effect of dermorphin 
(Paakkari and Feuerstein, 1988). However, in cen-
trast to our present results, flumazenil did not an-
tagonize the respiratory depressant effect of i. v. 
injected morphine in rabbits (Bonetti et al., 1982). 
The discrepancy may be due to the different species, 
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Fig. I. Effect of dennorphin I nmol, i .c. v. (DM I) on ventilation rate (VR) and ventilation minute volume 
(MV). ALP= alprazolam, NAL = naloxone, FLU = flumazenil. (A) Time-course of the changes in VR 
after treatment. Two-way ANOV A for repeated measures: group P < 0.00 1, time P = 0.24, interaction 
P < 0.05. • P < 0.05 when compared to the base line, dependent I-test. (B) VR area scores between 
94-114 min after treatment. One-way ANOV A between the groups: P < 0.05, • P < 0.05 DM 1 vs 
FLU + DM 1 (Dunnett's test). (C) Time-course of the changes in MV after treatment. Two-way ANOV A 
for repeated measures: group P = 0.35, time P = 0.48, interaction P < 0.32. • P < 0.05 when compared 
to the base line, dependent I-test. (D) MV area scores between 94-114 min after treatment. One-way 
ANOV A between the groups P = 0.37, • P < 0.05 DM 1 vs all other treatments (Contrast analysis). 
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Fig. 2. Effect of dermorphin 3 nmol, i.c.v. (DM3) on ventilationrate (VR) and Ventilationminute volume 
(MV). ALP= alprazolam, FLU = ftumazenil. (A) Time-course of the changes in VR after treatment. 
Two-way AN OVA for repeated measures: group P < 0.369, time P < 0.001, interaction P < 0.087. 
*P < 0.05, ••p < 0.01 and •••p < 0.001 when compared to the base line (dependent t-test). (B) VR 
area scores between 94-114 min after treatment. Kruskal-Wallis ANOVA P = 0.098, Median test 
P < 0.05. (C) Time-i:ourse of the changes in MV after treatment. Two-way ANOV A for repeated 
measures: group P = 0.076, time P < 0.00 I, interaction P < 0.05. • P < 0.05, ••• P < 0.00 l when com-
pared to the base line (dependent t-test). (D) MV area scores between 94-114 min after treatment. 
Kruskal-Wallis ANOVA P < 0.05, Mediantest P < 0.01, P < 0.05 DM3 vs all other treatments (Contrast 
analysis). 
or the use of different method in measuring the 
respiration. In the rabbit flumazenil-morphine study, 
the animals were mechanically immobilized and a 
mask with a pressure transducer was attached to the 
snout. In the present experiment the recordings were 
made from freely moving uninstrumented animals 
utilizing a fully automated, non·invasive system. Ac· 
cordingly, the present results would reflect the opioid 
regulation of respiration in the absence of any major 
physical constraint. The assumption that changing 
the methodology may change the results is supported 
by the studies ofWard and Takemori (1983). In their 
study, ß-funaltrexamine antagonized morphine· 
induced respiratory depression when the respiratory 
rate was recorded by body pletysmograph, whereas 
there was no antagonism when the rats were immobi· 
lized and the respiratory rate was counted by placing 
the snout of the mouse into the barret of a syringe 
connected to a pressure transducer. 
The interactions between benzodiazepine and opi· 
oid agonists in producing analgesia are complicated. 
Benzodiazepines have antagonized (Mantegazza et 
al., 1982; Abott and Franklin, 1986) and enhanced 
(Moreau and Pieri, 1988; Bergman, Wynn, Peterson 
and Rudo, 1988) the antinociceptive effects of opi· 
oids. Alprazolam bad likewise dual effects on dermor-
phin-induced respiratory depression in the present 
study. It potentiated the decrease in respiratory 
minute volume induced by the lowest dose of dermor-
phin, but the effect of higher doses of dermorphin 
on all respiratory parameters was attenuated. 
The cataleptic effect of high doses of dermorphin 
(Paakkari and Feuerstein, 1988) may decrease the 
respiratory movements of the thorax and thus aug-
ment the respiratory depression. The well known 
muscle relaxing effect of benzodiazepines may partly 
explain the antagonistic effect of alprazolam. 
Recently Rattan and coworkers (1991) reported an 
antinociceptive benzodiazepine-opioid interaction 
that is similar to our results. In the rat tail-flick test, 
midazolam (10 Jlg, i.t.) potentiated the antinocicep-
tive etfect of a low dose (10 Jlg, i.t.) of morphine, but 
antagonized the effect of higher doses (20 or 30 Jl g). 
In binding sturlies in rat spinal cord homogenates, the 
authors found that midazolam at a low dose potenti-
ated the displacement of [3H]naloxone by morphine 
whereas at higher doses midazolam inhibited the 
morphine-induced displacement of [3H]naloxone. 
They suggest that in the presence of low concen-
trations of a benzodiazepine opioid receptors are 
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modulated in such a fashion that they have a higher 
affinity for morphine. This type of interaction could 
theoretically explain the dual effects of alprazolam in 
our studies. However, the binding sturlies were done 
in spinal receptors whereas we gave the opioids i.c.v. 
and alprazolam i.p. 
The close relationship between opioid and benzo-
diazepine receptors is previously emphasized by the 
discovery of substituted 1 ,4-benzodiazepines which 
have no affinity for benzodiazepine binding sites but 
bind selectively on opiate receptors and act pharma-
cologically as opiates (Römer, Büscher, Hili, Maurer, 
Petcher, Zcugner, Benson, Finner, Milkowski and 
Thies, 1982). Furthermore, ß-carbolines or harma-
lines had affinity for both benzodiazepine and opiate 
receptors (Airaksinen and Mikkonen, 1980). The 
pure benzodiazepine Iigand ß -carboline, 3-hydrox-
ymethyl-ß -carboline reversed the cerebral metabolic 
and hypnotic effects of fturazepam (Mendelson, Cain, 
Cook, Paul and . Skolnick, 1983; Hotfmann, Feld, 
Larscheid, Cook, Albrecht and Miletich, 1985) as 
well as respiratory depression induced by the opiate 
fentanyl (Naughton, Hoffman, Larscheid, Cook, 
Albrecht and Miletich, 1985). Benzodiazepines also 
influence opiate receptor ontogeny: prenatal exposure 
140 A 
Q) 
to diazepam decreased opiate binding sites in rat 
brain at 14 days of age (Watanabe, Shibuya, Salafsky 
and Hili, 1983). 
On the basis of our in vivo results it is impossible 
to determine whether the opioid-benzodiazepine 
interactions observed are due to allosteric modu-
lation of opioid binding by benzodiazepines, or 
whether the opioid and benzodiazepine/GABAergic 
pathways intervene physiologically. Interaction 
between these systems was implied by Waldrop, 
Eldridge and Millhorn (1983), who suggested that the 
depression of breathing that follows hindlimb muscle 
Stimulation is mediated by endogenous opiates and 
GABA. 
The respiratory depressant effect of barbiturates 
may, at least partly, be due to their enhancing effect 
on GABAergic transmission (Olsen 1981 ), since 
GABA and GABAergic drugs are known to produce 
ventilatory depression (Yamada, Hamosh and Gillis, 
1981; Hedner, Hedner, Wessberg and Jonason 1984; 
Da Silva, Hartley, Hamosh, Quest and Gillis, 1987). 
A barbiturate-GABA-opioid interaction was re-
ported by Suria, Nasreen and Saeed ( 1988), who 
found that in the rat thiopental-induced respiratory 
depression was associated with an increase of GABA 
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Fig. 3. Effect of dermorphin 30 nmol, i.c.v. (DM30) on ventilation rate (VR) and ventilation minute 
volume (MV). FLU = flumazenil. (A) Time--amrse of the changes in VR after treatment. Two-way 
ANOVA for repeated measures: group P < 0.001, time P < 0.001, interaction P < 0.001. •••p < 0.001 
when compared to the base line, dependent I-test. (8) VR area scores between 94-114 min after treatment. 
ANOVA p = <0.001, •••p < 0.001 DM30 vs FLU + DM30 or NaCI, Newman-Keul test. (C) 
Time-course of the changes in MV after treatment. Two-way ANOV A for repeated measures: group 
p = 0.001, time P < 0.01, interaction P < 0.00 1. •• P < 0.0 I and ... P < 0.00 I when compared to the base 
line, dependent t-test. (D) MV area scores between 94-114 min after treatment. ANOVA P < 0.001, 
••• P < 0.001 DM30 vs FLU + DM30 of NaCl. 
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in brain stem, and naloxone 2.5 mg/kg reversed both 
the respiratory paralysis and the increase of GABA 
Ievels. The strong antagonistic effect of ftumazenil on 
dermorphin-induced respiratory depression suggests 
that benzodiazepinejGABAergic receptors and/or 
pathways take part also in opioid induced respiratory 
depression, analogaus to interactions implied in 
analgesic, gastrointestinal and cataleptic actions of 
opioids. 
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